Blockade of CB1R in islets for therapeutic purposes in type 2 diabetes has been explored by us and others; the capability of this blockade in preventing beta cell identity loss has not been deeply explored even though CB1R regulates pancreatic islet microarchitecture during development. The gene discussed is CNR1; the disease is type 2 diabetes mellitus.